Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Identification of e6a2 BCR-ABL fusion in a Philadelphia-positive CML with marked basophilia: implications for treatment strategy.

Rohon P, Divoka M, Calabkova L, Mojzikova R, Katrincsakova B, Rusinakova Z, Lapcikova A, Raida L, Faber E, Jarosova M, Divoky V, Indrak K.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011 Jun;155(2):187-90.

2.

Chronic myelogenous leukemia: molecular and cellular aspects.

Pasternak G, Hochhaus A, Schultheis B, Hehlmann R.

J Cancer Res Clin Oncol. 1998;124(12):643-60. Review.

PMID:
9879825
3.

Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.

Kawano N, Okuda S, Yoshida S, Kugimiya H, Ito M, Horikawa N, Chosa N, Hisakata T, Fukudome T, Sakurai R, Yamashita K, Ueda A, Kanda Y.

Int J Hematol. 2011 Dec;94(6):561-6. doi: 10.1007/s12185-011-0956-y. Epub 2011 Nov 8.

PMID:
22057509
4.

E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.

Popovici C, Cailleres S, David M, Lafage-Pochitaloff M, Sainty D, Mozziconacci MJ.

Leuk Lymphoma. 2005 Sep;46(9):1375-7.

PMID:
16109618
5.

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.

Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.

Med Oncol. 2004;21(4):349-58.

PMID:
15579919
6.

Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation.

Neumann F, Herold C, Hildebrandt B, Kobbe G, Aivado M, Rong A, Free M, Rössig R, Fenk R, Schneider P, Gattermann N, Royer-Pokora B, Haas R, Kronenwett R.

Eur J Haematol. 2003 Jan;70(1):1-10.

PMID:
12631253
8.

Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.

Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Savoldo B, Rizzo MT, Rizzoli V.

Blood. 1996 Oct 15;88(8):3091-100.

9.

Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.

Jiang X, Saw KM, Eaves A, Eaves C.

J Natl Cancer Inst. 2007 May 2;99(9):680-93.

PMID:
17470736
10.

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ.

J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24.

11.

Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.

Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.

Oncogene. 2002 Nov 21;21(53):8075-88.

12.

Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.

Oshikawa G, Kurosu T, Arai A, Murakami N, Miura O.

Cancer Genet Cytogenet. 2010 May;199(1):56-61. doi: 10.1016/j.cancergencyto.2010.01.018.

PMID:
20417871
13.

Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia.

Hur M, Song EY, Kang SH, Shin DH, Kim JY, Park SS, Cho HI.

Ann Hematol. 2002 Apr;81(4):219-23. Epub 2002 Feb 28. Review.

PMID:
11976825
14.

Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.

Warmuth M, Danhauser-Riedl S, Hallek M.

Ann Hematol. 1999 Feb;78(2):49-64. Review.

PMID:
10089019
15.

Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.

Morel F, Bris MJ, Herry A, Calvez GL, Marion V, Abgrall JF, Berthou C, Braekeleer MD.

Eur J Haematol. 2003 Apr;70(4):235-9.

PMID:
12656747
16.
17.

[Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene].

Qin YZ, Liu YR, Li JL, Wang H, Chang Y, Fu JY, Ruan GR, Shi HL, Qiu JY, Lu DP, Chen SS.

Zhonghua Xue Ye Xue Za Zhi. 2004 Jul;25(7):409-12. Chinese.

PMID:
15355693
18.

Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft.

Corsetti MT, Lerma E, Dejana A, Cavaliere M, Figari O, Vassallo F, Abate M, Luchetti S, Piaggio G, Parodi C, Li Pira G, Manca F, Carella AM.

Exp Hematol. 2000 Jan;28(1):104-11. Erratum in: Exp Hematol. 2000 Mar;28(3):347. multiple abstract errors corrected.

PMID:
10658682
20.

Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.

Drexler HG, MacLeod RA, Uphoff CC.

Leuk Res. 1999 Mar;23(3):207-15. Review.

PMID:
10071072

Supplemental Content

Support Center